Hazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays.
bath salts
designer drugs
hazard characterization
in vitro neurotoxicity assays
synthetic cathinones
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
08
2019
accepted:
07
01
2020
entrez:
18
2
2020
pubmed:
18
2
2020
medline:
18
2
2020
Statut:
epublish
Résumé
Synthetic cathinones are the second largest class of new psychoactive substances (NPS) on the drug market. Despite the large number of different cathinones and their abundant use, hazard characterization is mainly limited to their potential to inhibit monoamine transporters. To expand the current hazard characterization, we first investigated the acute effects of several synthetic cathinones [4-methylethcathinone (4-MEC), 3-methylmethcathinone (3-MMC), 4-MMC, methylone, pentedrone, α-pyrrolidinovalerophenone (α-PVP), and 3,4-methylenedioxypyrovalerone (MDPV)] on human dopamine, norepinephrine, and serotonin reuptake transporters (hDAT, hNET, and hSERT), which were stably transfected in human embryonic kidney (HEK) 293 cells. Next, we examined effects on spontaneous neuronal activity in rat primary cortical cultures grown on microelectrode arrays (MEAs) as an integrated endpoint for neurotoxicity. Changes in neuronal activity were assessed after acute (30 min) and prolonged (4.5 h) exposure. Moreover, we investigated whether neuronal activity recovered after washout of the exposure (24 h after the start of the 5 h exposure). Low micromolar concentrations of synthetic cathinones inhibited monoamine uptake via hDAT and hNET, while higher cathinone concentrations were needed to inhibit uptake via hSERT. Comparable high concentrations were needed to inhibit spontaneous neuronal activity during acute (30 min) and prolonged (4.5 h) exposure. Notably, while the inhibition of neuronal activity was reversible at low concentrations, only partial recovery was seen following high, but non-cytotoxic, concentrations of synthetic cathinones. Synthetic cathinones with either a pyrrolidine moiety or long alkyl-tail carbon chain more potently inhibit monoamine uptake via hDAT and neuronal activity. Monoamine uptake via hNET was most potently inhibited by synthetic cathinones with a pyrrolidine moiety. The combination of integrated measurements (MEA recordings of neuronal activity) with single target assays (monoamine reuptake transporter inhibition) indicates inhibition of hDAT and hNET as the primary mode of action of these synthetic cathinones. Changes in neuronal activity, indicative for additional mechanisms, were observed at higher concentrations.
Identifiants
pubmed: 32063828
doi: 10.3389/fnins.2020.00009
pmc: PMC7000521
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
Copyright © 2020 Zwartsen, Olijhoek, Westerink and Hondebrink.
Références
J Pharmacol Exp Ther. 2011 Nov;339(2):530-6
pubmed: 21810934
J Anal Toxicol. 2013 Apr;37(3):135-46
pubmed: 23361867
Clin Toxicol (Phila). 2015 Jan;53(1):46-53
pubmed: 25422862
Forensic Sci Int. 2011 Jul 15;210(1-3):195-200
pubmed: 21477955
J Anal Toxicol. 2015 May;39(4):324-9
pubmed: 25737339
Psychopharmacology (Berl). 2013 Sep;229(2):295-306
pubmed: 23649883
J Med Toxicol. 2012 Dec;8(4):360-77
pubmed: 23055123
Front Psychiatry. 2017 Nov 17;8:232
pubmed: 29204126
Neurosci Lett. 2004 Jan 16;354(3):209-12
pubmed: 14700733
Drug Test Anal. 2017 Mar;9(3):358-368
pubmed: 27524685
J Anal Toxicol. 2013 Apr;37(3):182-5
pubmed: 23408250
Neurotoxicology. 2016 Dec;57:194-202
pubmed: 27720795
Neuroscience. 2007 May 25;146(3):1193-211
pubmed: 17408864
Neuropharmacology. 2014 Dec;87:206-13
pubmed: 24594476
J Anal Toxicol. 2013 Mar;37(2):74-82
pubmed: 23354334
J Biomed Sci. 2010 May 11;17:36
pubmed: 20459778
J Neurosci Methods. 2008 Mar 30;169(1):168-76
pubmed: 18222006
Br J Pharmacol. 2013 Jan;168(2):458-70
pubmed: 22897747
Adv Pharmacol. 2014;69:581-620
pubmed: 24484988
J Med Toxicol. 2010 Sep;6(3):327-30
pubmed: 20358417
J Forensic Sci. 2017 May;62(3):695-699
pubmed: 27921290
Clin Toxicol (Phila). 2016 Aug;54(7):568-75
pubmed: 27412885
Neurotoxicology. 2017 May;60:280-292
pubmed: 27036093
J Pharmacol Exp Ther. 2017 Jan;360(1):33-47
pubmed: 27799294
J Anal Toxicol. 2012 Jul;36(6):434-9
pubmed: 22582221
Neuropharmacology. 2017 Sep 1;123:1-9
pubmed: 28454981
J Med Toxicol. 2012 Sep;8(3):310-3
pubmed: 22528592
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:64-72
pubmed: 23603357
J Addict Med. 2013 May-Jun;7(3):153-62
pubmed: 23732954
Biochem Pharmacol. 2013 Jun 15;85(12):1803-15
pubmed: 23583454
Neuropsychopharmacology. 2013 Mar;38(4):552-62
pubmed: 23072836
Forensic Sci Int. 2014 Oct;243:68-73
pubmed: 24846124
Curr Top Behav Neurosci. 2017;32:49-72
pubmed: 27272068
Synapse. 2001 Sep 1;41(3):203-11
pubmed: 11391781
Drug Test Anal. 2016 Jan;8(1):63-70
pubmed: 26666629
ACS Chem Neurosci. 2015 Oct 21;6(10):1726-31
pubmed: 26217965
ACS Chem Neurosci. 2013 Jan 16;4(1):182-90
pubmed: 23336057
Forensic Sci Int. 2014 Oct;243:55-60
pubmed: 24810679
Neurotoxicology. 2019 Sep;74:28-39
pubmed: 31078573
Forensic Toxicol. 2018;36(1):33-50
pubmed: 29367861
J Forensic Sci. 2017 Mar;62(2):553-556
pubmed: 28028802
Neuropsychopharmacology. 2015 May;40(6):1321-31
pubmed: 25502630
ACS Chem Neurosci. 2013 Dec 18;4(12):1524-9
pubmed: 24116392
Neurotoxicology. 2018 May;66:87-97
pubmed: 29572046
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):192-204
pubmed: 20036748
Pharmacol Ther. 2018 Feb;182:193-224
pubmed: 29097307
Toxicol In Vitro. 2017 Dec;45(Pt 1):60-71
pubmed: 28506818
J Neurochem. 2010 Aug;114(4):1019-29
pubmed: 20524964
Arch Toxicol. 2018 Jan;92(1):487-500
pubmed: 28766123
Neuropharmacology. 2014 Apr;79:152-60
pubmed: 24275046